Hemogenyx Pharmaceuticals has signed a research agreement through is subsidiary Immugenyx, to develop humanized mice as a tool for drug development and testing, including with a global pharmaceutical company, whose identity must remain hidden at its request.
Hemogenyx revealed that this hidden company will pay $75,000 to Immugenyx for the research it conducts.
According to the Agreement, Immugenyx will grant the company a worldwide, non-exclusive, royalty-free licence to any know-how and any patents and patent applications arising from the Agreement to use solely for their own research and product development purposes.
This agreement is a continuation of Hemogenyx’s deal for CDX antibodies with the same company from May 2018.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx, said that this global pharmaceutical company is a leader in the field of cancer and autoimmune disease treatment.
“The advancement of this research and potential future collaborations serve both as a validation of our technology and a means of support for the further development of our CDX bi-specific antibody product candidate,” he said.